Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Increased precursor microRNA-21 following status epilepticus can compete with mature microRNA-21 to alter translation.

Chak K, Roy-Chaudhuri B, Kim HK, Kemp KC, Porter BE, Kay MA.

Exp Neurol. 2016 Dec;286:137-146. doi: 10.1016/j.expneurol.2016.10.003. Epub 2016 Oct 8.

2.

Function of the Drosophila receptor guanylyl cyclase Gyc76C in PlexA-mediated motor axon guidance.

Chak K, Kolodkin AL.

Development. 2014 Jan;141(1):136-47. doi: 10.1242/dev.095968. Epub 2013 Nov 27.

3.

The extracellular matrix proteoglycan perlecan facilitates transmembrane semaphorin-mediated repulsive guidance.

Cho JY, Chak K, Andreone BJ, Wooley JR, Kolodkin AL.

Genes Dev. 2012 Oct 1;26(19):2222-35. doi: 10.1101/gad.193136.112.

4.

A combinatorial semaphorin code instructs the initial steps of sensory circuit assembly in the Drosophila CNS.

Wu Z, Sweeney LB, Ayoob JC, Chak K, Andreone BJ, Ohyama T, Kerr R, Luo L, Zlatic M, Kolodkin AL.

Neuron. 2011 Apr 28;70(2):281-98. doi: 10.1016/j.neuron.2011.02.050.

5.

Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer.

Mok TS, Ho S, Chan G, Ho WM, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Lee Y, Lam KC.

J Thorac Oncol. 2007 Sep;2(9):838-44.

6.

A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity.

Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B.

Ann Oncol. 2007 Apr;18(4):768-74. Epub 2007 Jan 17.

PMID:
17229769
7.

Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.

Mok TS, Lam KC, Lee C, Zhang L, Wong H, Chan AT, Yeo W, Yim AP, Chak K, Zee B.

Oncology. 2005;68(4-6):485-92. Epub 2005 Jul 13.

PMID:
16020979
8.

Shyness and locus of control as predictors of internet addiction and internet use.

Chak K, Leung L.

Cyberpsychol Behav. 2004 Oct;7(5):559-70.

PMID:
15667051
9.

A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer.

Mok TS, Leung TW, Brown G, Moyses C, Chan AT, Yeo W, Wong H, Chak K, Johnson P.

Acta Oncol. 2004;43(3):245-51.

PMID:
15244247
10.

Reprogramming control of an allosteric signaling switch through modular recombination.

Dueber JE, Yeh BJ, Chak K, Lim WA.

Science. 2003 Sep 26;301(5641):1904-8.

11.

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.

Cancer. 2002 Oct 1;95(7):1511-9.

12.

Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.

Mok TS, Kanekal S, Lin XR, Leung TW, Chan AT, Yeo W, Yu S, Chak K, Leavitt R, Johnson P.

Cancer. 2001 Jun 15;91(12):2369-77.

PMID:
11413527
13.

Clinical outcomes of post-operative locoregional radiotherapy in pre-menopausal and post-menopausal Chinese women with breast cancer.

Mok TS, Kwan WH, Yeo WM, Chan AT, Chan EC, Chak K, Chow DL, Lo C, Leung TW, Teo PM.

Radiother Oncol. 2000 Mar;54(3):201-8.

PMID:
10738077
14.

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma.

Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, Lui MC, Yeo W, Chak K, Johnston A, Johnson P.

Cancer Chemother Pharmacol. 1999;44(4):307-11.

PMID:
10447578

Supplemental Content

Loading ...
Support Center